Porownywarka
ACE-031 vs Kisspeptin side-by-side
Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.
Porownywarka
Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.
Wybrane (2/4)
Udostępnij porównanie peptydów
| Wlasciwosc | ACE-031 | Kisspeptin |
|---|---|---|
| Kategoria | Hormonalne | Hormonalne |
| Znany tez jako | ACVR2B-Fc, Myostatin Inhibitor | Kisspeptin-10, Kisspeptin-54, Metastin |
| Zatwierdzony przez FDA | Nie | Nie |
| Status kliniczny | Development halted due to safety concerns
| Investigational - Clinical trials ongoing Nie dotyczy |
| Czego oczekiwac | Muscle growth research, muscular dystrophy | Fertility, testosterone, reproductive hormone optimization |
| Jak dziala | ACE-031 is an ACVR2B-Fc fusion protein designed to function as a circulating ligand trap. The source describes it as binding myostatin and related TGF-beta superfamily ligands before they can signal through activin type IIB receptors on muscle. This pathway was investigated as a way to reduce growth-inhibitory signaling. Reported bleeding and telangiectasia findings are consistent with concern that activin-receptor signaling also affects vascular biology. | Kisspeptin is described as acting through KISS1R/GPR54 receptors on GnRH neurons in the hypothalamus. The reported intracellular pathway includes phospholipase C activation with IP3 and DAG second messengers, followed by increased GnRH release. GnRH then drives pituitary gonadotropin output, including LH and FSH, linking kisspeptin signaling to ovarian and testicular hormone regulation. The source also notes genetic evidence: inactivating KISS1 or KISS1R mutations are associated with pubertal failure and infertility, while activating mutations are associated with precocious puberty. |
| Typowe dawkowanie | Limited community data available · See research protocols | 100-200 mcg subcutaneously once daily · Once daily or every other day |
| Dawkowanie z badań | 0.5-3 mg/kg every 2 weeks in trials · Every 2 weeks in trials · Trials discontinued · Subcutaneous injection | Kisspeptin-10: 1-10 nmol/kg IV · Variable by protocol · IV (research), subcutaneous (investigational) |
| Typowy czas trwania | Trials discontinued | Variable by protocol |
| Podanie | Subcutaneous injection | IV (research), subcutaneous (investigational) |
| Timing | Morning, same day each week With or without food | Morning or as directed With or without food |
| Poziom dowodów | Badania kliniczne | Badania kliniczne |
| Mozliwe skutki uboczne |
+3 więcej
|
+3 więcej
|
| Podsumowanie researchu | The source describes ACE-031 as having been evaluated in humans, including single-ascending-dose work in healthy volunteers and an ascending-dose, placebo-controlled Phase 2 study in ambulatory boys with Duchenne muscular dystrophy. Reported study signals included changes related to lean mass, fat mass, bone measures and 6-minute walk distance. The Duchenne study stopped early after safety findings such as nosebleeds and telangiectasias, and the broader program was discontinued despite no serious or severe adverse events being formally attributed in the source summary. | The supplied evidence reports several human research contexts. In women with hypothalamic amenorrhea, subcutaneous kisspeptin-54 was reported to raise LH about 10-fold and FSH about 2.5-fold into the normal range, and infusion protocols were reported to restore LH pulse frequency. In an IVF setting, kisspeptin-54 was used to trigger oocyte maturation, with a live term birth reported, and the source says it has been explored as a potentially gentler trigger with possible ovarian hyperstimulation risk reduction. In hypogonadal men, kisspeptin-10 infusion reportedly increased LH roughly 5-fold and moved testosterone into the normal range. The same source cautions that these data mainly come from small academic studies and specialist infusion protocols, not large multi-center phase 3 trials, and that short-term hormone changes do not establish long-term safety. |
| Referencje | ||
| Pełny profil | Zobacz szczegóły | Zobacz szczegóły |
Zapisz to porównanie
Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.
Zapisz porównanie - darmowe kontoTrackuj swoja ścieżkę peptydówa
Zamien research w prywatny log protokołu, gdy będziesz gotowy.
Trackuj ścieżkę peptydówaWyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.